Verneuil Vanina De Sells 2,347 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 2,347 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $9.47, for a total transaction of $22,226.09. Following the transaction, the executive vice president now owns 61,370 shares in the company, valued at $581,173.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Verneuil Vanina De also recently made the following trade(s):

• On Friday, November 1st, Verneuil Vanina De sold 1,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.20, for a total transaction of $10,101.60.

Vir Biotechnology Trading Up 5.5 %

NASDAQ:VIR opened at $10.17 on Thursday. Vir Biotechnology, Inc. has a 1 year low of $7.12 and a 1 year high of $13.09. The firm’s fifty day simple moving average is $7.80 and its 200 day simple moving average is $8.90. The firm has a market capitalization of $1.39 billion, a PE ratio of -2.59 and a beta of 0.46.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The firm had revenue of $2.38 million during the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business’s quarterly revenue was down 9.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.22) earnings per share. As a group, analysts anticipate that Vir Biotechnology, Inc. will post -3.48 EPS for the current fiscal year.

Institutional Trading of Vir Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of VIR. Blue Trust Inc. grew its position in Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after purchasing an additional 2,351 shares during the last quarter. Innealta Capital LLC acquired a new stake in Vir Biotechnology in the 2nd quarter worth $32,000. nVerses Capital LLC acquired a new stake in shares of Vir Biotechnology during the 3rd quarter valued at about $56,000. Magnetar Financial LLC acquired a new stake in shares of Vir Biotechnology during the 2nd quarter valued at about $95,000. Finally, Quest Partners LLC boosted its position in shares of Vir Biotechnology by 142.1% during the 2nd quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after acquiring an additional 7,452 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

VIR has been the topic of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Friday, November 1st. Barclays cut their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Monday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).